How to Get Wegovy Prescribed for Weight Loss (2026)

TL;DR

• Wegovy requires a BMI of 30+, or 27+ with a weight-related condition, confirmed by a licensed clinician.
• GoodLife Health's $299/month Cardiometabolic Optimization Membership includes quarterly labs and prescribing with medication billed at pharmacy cost.
• Semaglutide produced roughly 15% average weight loss in the STEP-1 trial; individual results vary.
• Compounded semaglutide is not Wegovy and is not something a legitimate GLP-1 clinic should offer in 2026.
• Verdict: choose a clinician who orders labs before writing anything, not a form that greenlights a script off BMI alone.

Why this matters

Wegovy is semaglutide, the same molecule as Ozempic, but it's the formulation and dose specifically FDA-approved for chronic weight management rather than type 2 diabetes. That distinction matters because a prescription written for the wrong indication can get denied at the pharmacy counter, and a clinician who skips it entirely is skipping the part of the visit that actually protects you.

GoodLife Health treats a Wegovy prescription as one output of a bigger diagnostic picture, not a standalone transaction.

The other reason this matters in 2026: demand for GLP-1 medications has pulled in a wave of platforms that write prescriptions off a five-minute questionnaire and route patients to compounded semaglutide when brand-name supply tightens. Compounded GLP-1s are not FDA-approved copies of Wegovy. They're a different regulatory category entirely, and no legitimate clinic should be substituting one for the other without telling you.

What you'll need

• Baseline labs — a lipid panel, HbA1c, and ideally ApoB and hs-CRP, drawn before your first prescribing decision, not after
• A licensed clinician in your state, working from a documented protocol rather than a chatbot script
• BMI documentation or a qualifying comorbidity — hypertension, type 2 diabetes, or obstructive sleep apnea alongside a BMI of 27 or higher
• 20 to 30 minutes for an intake visit where someone actually reviews your history
• A pharmacy relationship that can fill branded Wegovy, since supply varies by region and by month

Here's how the current branded GLP-1 lineup breaks down, since patients frequently confuse the names:

Zepbound and Mounjaro are the same molecule prescribed for different indications; the same logic applies to Wegovy and Ozempic. Getting matched to the right one on the label that fits your situation is part of what a clinician is actually doing during that intake visit.

The steps

1. Get baseline labs before anyone talks dosing

A lipid panel, HbA1c, and inflammatory markers tell a clinician whether you're dealing with insulin resistance, elevated ApoB, or systemic inflammation alongside excess weight — all of which change how aggressively weight loss should be pursued and monitored. Skipping this step is the single most common shortcut low-quality telehealth platforms take. Expected outcome: a documented set of numbers your clinician references at every follow-up, not just at intake. Common mistake: accepting a prescription decision based on a self-reported BMI with no lab data behind it.

2. Confirm you meet the clinical eligibility bar

Wegovy's FDA-approved use covers a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like hypertension, type 2 diabetes, or sleep apnea. Your clinician should confirm this with your actual height, weight, and health history, not just take your word for a number. Expected outcome: a documented eligibility determination in your chart before the script goes anywhere. Common mistake: assuming eligibility is a formality that any provider will rubber-stamp.

3. Pick the care model that fits how you want to be treated

You can pursue Wegovy through a traditional insurance-based primary care visit, a subscription telehealth platform, or a direct primary care membership. Each has different visit lengths, different lab cadences, and different pricing structures for the medication itself. A direct primary care doctor can prescribe GLP-1 medications the same way any licensed physician can, but the membership model typically includes the labs and follow-up visits that a per-visit telehealth subscription bills separately. Expected outcome: you know before your first visit what's included and what isn't. Common mistake: choosing a provider based on speed to prescription rather than what happens at month three.

4. Complete the intake visit and answer the medical history honestly

Expected outcome: a written treatment plan, not just a script sent to the pharmacy. Common mistake: underreporting GI symptoms because you're worried it'll disqualify you; it usually just changes the starting dose or monitoring plan.

5. Understand exactly what you'll pay before you fill it

Brand-name Wegovy without insurance runs into real money, and pricing shifts based on pharmacy, dose, and whether your plan covers it at all — the Wegovy cost without insurance breakdown covers current numbers in detail. What should never happen: a clinic marking up the medication itself or adding a fee that scales with your dose as you titrate up.

Expected outcome: a clear number before you commit, not a surprise at the pharmacy counter. Common mistake: signing up with a provider that reprices the medication every time your dose increases.

6. Start the titration schedule and expect a slow ramp

Wegovy starts at a low dose and increases roughly every four weeks to reduce GI side effects, ending at the maintenance dose over several months. In the STEP-1 trial, participants on semaglutide lost an average of about 15% of body weight over 68 weeks compared to placebo — that's a trial average, not a guarantee, and results vary by person, adherence, and starting point. Expected outcome: gradual appetite change over the first four to eight weeks, not overnight results. Common mistake: expecting rapid loss in week one and stopping early when it doesn't happen.

7. Book the 90-day recheck before you forget

Labs and weight response should be reassessed roughly every 90 days so your clinician can adjust dose, catch any lipid or glucose shifts, and confirm the plan is still working. This is also when hormone and thyroid panels get rechecked if those are part of your broader plan. Expected outcome: a documented trend line across at least two lab draws before major decisions get made. Common mistake: treating the first prescription as the finish line instead of the start of an ongoing relationship.

Troubleshooting

Insurance denies coverage for Wegovy. Insurers frequently require prior authorization and documented BMI plus a failed attempt at lifestyle intervention before approving weight-management indications. If denied, ask your clinician about appeal documentation or discuss cash-pay pricing directly rather than assuming the medication is off the table.

A provider only asks your BMI and skips labs entirely. That's a red flag, not a shortcut. Weight, blood sugar, and lipids move together, and a clinician prescribing without baseline labs is missing the data that should inform your starting dose and monitoring plan.

You're offered compounded semaglutide instead of Wegovy. Compounded GLP-1s are not FDA-approved copies of branded medication, and no clinic operating under proper clinical protocols in 2026 should be substituting one for the other without telling you plainly. Ask directly whether the medication is branded and FDA-approved before you agree to anything.

Nausea or GI upset in the first few weeks. This is common during dose escalation and typically improves as your body adjusts; smaller meals and slower titration usually help more than stopping the medication outright. Report it to your clinician rather than adjusting the dose yourself.

The pharmacy says Wegovy is out of stock. Supply has fluctuated by region and by month; ask your clinician about alternate pharmacies or whether a comparable branded option fits your case while supply catches up.

Your provider adds a fee every time your dose increases. That's dose-escalation repricing, and it means the business model benefits when your dose goes up rather than when your health improves. A flat membership fee with medication billed at pharmacy cost avoids that incentive entirely.

Tools and resources

• Baseline lab panel (lipids, HbA1c, ApoB, hs-CRP) run through a certified lab network before your first prescribing decision
• A licensed clinician working under documented clinical protocols, not an unsupervised intake form
• A pharmacy that can fill branded Wegovy at your dose
• A follow-up cadence — ideally every 90 days — to reassess labs and adjust the plan

What to do next

If you haven't had a telehealth intake visit before, read through what to expect at your first telehealth weight loss consultation so you know what questions your clinician should be asking and what labs should get ordered before anything gets prescribed.

FAQ

What's the best way to get Wegovy prescribed for weight loss?

The reliable path is a licensed clinician who orders baseline labs, confirms your BMI or qualifying condition, and documents a treatment plan before writing the prescription. Avoid any provider that skips labs and prescribes off a self-reported BMI alone.

Is Wegovy better than Ozempic for weight loss?

Wegovy and Ozempic contain the same molecule, semaglutide, but Wegovy is the formulation and dose specifically FDA-approved for chronic weight management, while Ozempic is approved for type 2 diabetes. Your clinician will match you to the one that fits your diagnosis and insurance coverage.

How much does Wegovy cost without insurance in 2026?

Pricing varies by pharmacy, dose, and region, and the full breakdown is covered in GoodLife Health's Wegovy cost guide. Look for a provider that bills the medication at pharmacy cost with no markup rather than adding fees as your dose increases.

Do I need to see a doctor in person to get Wegovy?

No — a licensed telehealth clinician can prescribe Wegovy after a video intake visit that reviews your history and orders labs, as long as they're licensed in your state. What matters more than in-person versus virtual is whether labs and a documented plan are part of the visit.

What BMI do you need for Wegovy?

Wegovy's FDA-approved use covers a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or sleep apnea. A clinician confirms this against your actual height and weight rather than a self-reported number.

Can a direct primary care doctor prescribe Wegovy?

Yes, a licensed physician working in a direct primary care model can prescribe Wegovy the same way any primary care doctor can. The difference is usually that a membership includes the labs and follow-up visits that a per-visit telehealth platform bills separately.

How long does it take to get approved for Wegovy?

A straightforward telehealth intake with labs already on file can result in a same-week prescribing decision, though pharmacy fulfillment and insurance prior authorization can add days to weeks. Cash-pay patients through a direct-billing pharmacy model typically move faster than insurance-dependent paths.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is not an FDA-approved copy of Wegovy and falls under a different regulatory category entirely. A legitimate clinic operating under documented clinical protocols in 2026 should never present compounded semaglutide as equivalent to branded Wegovy.

One last thing

The detail most patients miss: the STEP-1 trial's roughly 15% average weight loss was measured over 68 weeks of continuous treatment and lifestyle support, not a few months. Any plan that implies fast, effortless results ahead of that timeline is setting expectations the medication and the data don't support. Diet and activity changes still matter alongside the medication — GLP-1 therapy changes appetite signaling, it doesn't replace the basics.

Related guides

• How to talk to your doctor about starting GLP-1 therapy

References

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/